References:
1. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
2. Pappas PG et al. Nat Rev Dis Primers. 2018;4:18026.
3. Chatelon J et al. Adv Ther. 2019;36(12):3308–3320.
4. Góralska K et al. Infection. 2018;46(4):443–459.
5. Rüping MJGT et al. Drugs. 2008;68:1941–1962.
6. De Pascale G et al. Curr Opin Crit Care. 2015;21(5):421–429.
7. Muskett H et al. Crit Care 2011;15(6):R287.
8. Bulpa P et al. Eur Respir J 2007;30(4):782–800.
9. Xia R and Wang D Medicine 2019;98(44):e17704.
10. Brotfain E et al. Int J Surg Oncol 2017:6058567.
11. Gangneux JP et al. J Mycol Méd. 2020;30(2):100971.
12. AmBisome® Summary of Product Characteristics (UK). Available at:
https://www.medicines.org.uk/emc/product/1022/smpc#gref.
[Last accessed: March 2023].
13. Meletiadis J et al. J Antimicrob Agents Chemother. 2007;51(9):3329–3337.
14. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
15. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
16. Nett JE and Andes DR. Infect Dis Clin N Am. 2016;30(1):51–83.
17. Vadlapatla RK et al. Expert Opin Drug Metab Toxicol. 2014;10(4):561–580.
18. Chau MM et al. Internal Medicine Journal. 2021;51(Suppl. 7):37–66.
19. Morrell M et al. Antimicrob Agents Chemother. 2005;49(9):3640–3645.
20. Walsh TJ et al. N Engl J Med. 1999;340(10):764–771.
21. Falci DR et al. Mycoses. 2015;58(2):104–112.
22. Adler-Moore JP et al. Curr Opin Investig Drugs. 2003;4(2):179–185.
23. Keady S and Panesar P. EJHP Practice. 2010;16(3):78–80.
24. Stone NR et al. Drugs. 2016;76(4):485–500.
25. Adler-Moore JP et al. Med Mycol. 2016;54(3):223–231.
26. Wingard JT et al. Clin Infect Dis. 2000;31:1155–1163.
27. Walker L et al. MBio. 2018;9(1):e02383–e023417.
28. Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587–2590.
29. Meletiadis J et al. Antimicrob Agents Chemother. 2002;46(1):62–68.
References:
1. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
2. Pappas PG et al. Nat Rev Dis Primers. 2018;4:18026.
3. Chatelon J et al. Adv Ther. 2019;36(12):3308–3320.
4. Góralska K et al. Infection. 2018;46(4):443–459.
5. Rüping MJGT et al. Drugs. 2008;68:1941–1962.
6. De Pascale G et al. Curr Opin Crit Care. 2015;21(5):421–429.
7. Muskett H et al. Crit Care 2011;15(6):R287.
8. Bulpa P et al. Eur Respir J 2007;30(4):782–800.
9. Xia R and Wang D Medicine 2019;98(44):e17704.
10. Brotfain E et al. Int J Surg Oncol 2017:6058567.
11. Gangneux JP et al. J Mycol Méd. 2020;30(2):100971.
12. AmBisome® Summary of Product Characteristics (UK). Available at:
https://www.medicines.org.uk/emc/product/1022/smpc#gref. [Last accessed: March 2023].
13. Meletiadis J et al. J Antimicrob Agents Chemother. 2007;51(9):3329–3337.
14. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
15. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
16. Nett JE and Andes DR. Infect Dis Clin N Am. 2016;30(1):51–83.
17. Vadlapatla RK et al. Expert Opin Drug Metab Toxicol. 2014;10(4):561–580.
18. Chau MM et al. Internal Medicine Journal. 2021;51(Suppl. 7):37–66.
19. Morrell M et al. Antimicrob Agents Chemother. 2005;49(9):3640–3645.
20. Walsh TJ et al. N Engl J Med. 1999;340(10):764–771.
21. Falci DR et al. Mycoses. 2015;58(2):104–112.
22. Adler-Moore JP et al. Curr Opin Investig Drugs. 2003;4(2):179–185.
23. Keady S and Panesar P. EJHP Practice. 2010;16(3):78–80.
24. Stone NR et al. Drugs. 2016;76(4):485–500.
25. Adler-Moore JP et al. Med Mycol. 2016;54(3):223–231.
26. Wingard JT et al. Clin Infect Dis. 2000;31:1155–1163.
27. Walker L et al. MBio. 2018;9(1):e02383–e023417.
28. Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587–2590.
29. Meletiadis J et al. Antimicrob Agents Chemother. 2002;46(1):62–68.
This educational tool is developed and fully funded by Gilead Sciences, and it is intended for healthcare
professionals only. It contains information about Gilead products, educational materials on therapy areas,
and professional resources.
Prescribing information for Ambisome